413 related articles for article (PubMed ID: 32505834)
21. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
Patel AB; Verma A
JAMA; 2020 May; 323(18):1769-1770. PubMed ID: 32208485
[No Abstract] [Full Text] [Related]
22. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.
Gheblawi M; Wang K; Viveiros A; Nguyen Q; Zhong JC; Turner AJ; Raizada MK; Grant MB; Oudit GY
Circ Res; 2020 May; 126(10):1456-1474. PubMed ID: 32264791
[TBL] [Abstract][Full Text] [Related]
23. What would Sérgio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?
Nicolau LAD; Magalhães PJC; Vale ML
Med Hypotheses; 2020 Oct; 143():109886. PubMed ID: 32504925
[TBL] [Abstract][Full Text] [Related]
24. Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19.
Sparks MA; South A; Welling P; Luther JM; Cohen J; Byrd JB; Burrell LM; Batlle D; Tomlinson L; Bhalla V; Rheault MN; Soler MJ; Swaminathan S; Hiremath S
Clin J Am Soc Nephrol; 2020 May; 15(5):714-716. PubMed ID: 32220930
[No Abstract] [Full Text] [Related]
25. [Renin-angiotensin-aldosterone blockers and Covic-19 infection : friends or enemies ?].
Pechère-Bertschi A; Ponte B; Wuerzner G
Rev Med Suisse; 2020 May; 16(693):1003-1007. PubMed ID: 32401442
[TBL] [Abstract][Full Text] [Related]
26. [COVID-19 and its relationship with hypertension and cardiovascular disease].
Salazar M; Barochiner J; Espeche W; Ennis I
Hipertens Riesgo Vasc; 2020; 37(4):176-180. PubMed ID: 32591283
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin receptor blockers for the treatment of COVID-19 and its comorbidities.
Saavedra JM
Pharmacol Res; 2020 Sep; 159():104958. PubMed ID: 32473311
[No Abstract] [Full Text] [Related]
28. Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.
Ingraham NE; Barakat AG; Reilkoff R; Bezdicek T; Schacker T; Chipman JG; Tignanelli CJ; Puskarich MA
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32341103
[TBL] [Abstract][Full Text] [Related]
29. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
Cadegiani FA
Am J Physiol Endocrinol Metab; 2020 May; 318(5):E587-E588. PubMed ID: 32297520
[No Abstract] [Full Text] [Related]
30. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
Talreja H; Tan J; Dawes M; Supershad S; Rabindranath K; Fisher J; Valappil S; van der Merwe V; Wong L; van der Merwe W; Paton J
N Z Med J; 2020 Apr; 133(1512):85-87. PubMed ID: 32242182
[TBL] [Abstract][Full Text] [Related]
31. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
[TBL] [Abstract][Full Text] [Related]
32. Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.
Furuhashi M; Moniwa N; Takizawa H; Ura N; Shimamoto K
Hypertens Res; 2020 Aug; 43(8):837-840. PubMed ID: 32433641
[No Abstract] [Full Text] [Related]
33. [Hypertension and RAAS inhibition in times of COVID-19 - current recommendations of the European Society of Hypertension.].
Limbourg FP
MMW Fortschr Med; 2020 May; 162(9):67-69. PubMed ID: 32405833
[TBL] [Abstract][Full Text] [Related]
34. COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.
Siniorakis E; Arvanitakis S; Nikolopoulos I; Elkouris M
mBio; 2020 May; 11(3):. PubMed ID: 32444383
[No Abstract] [Full Text] [Related]
35. ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking.
Onweni CL; Zhang YS; Caulfield T; Hopkins CE; Fairweather L; Freeman WD
Crit Care; 2020 Jul; 24(1):475. PubMed ID: 32736573
[No Abstract] [Full Text] [Related]
36. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
Esler M; Esler D
J Hypertens; 2020 May; 38(5):781-782. PubMed ID: 32195824
[No Abstract] [Full Text] [Related]
37. Cross-Talk Between Key Players in Patients with COVID-19 and Ischemic Stroke: A Review on Neurobiological Insight of the Pandemic.
Kaushik P; Kaushik M; Parveen S; Tabassum H; Parvez S
Mol Neurobiol; 2020 Dec; 57(12):4921-4928. PubMed ID: 32813238
[TBL] [Abstract][Full Text] [Related]
38. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.
Conversano A; Melillo F; Napolano A; Fominskiy E; Spessot M; Ciceri F; Agricola E
Hypertension; 2020 Aug; 76(2):e10-e12. PubMed ID: 32383626
[No Abstract] [Full Text] [Related]
39. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.
Chung MK; Karnik S; Saef J; Bergmann C; Barnard J; Lederman MM; Tilton J; Cheng F; Harding CV; Young JB; Mehta N; Cameron SJ; McCrae KR; Schmaier AH; Smith JD; Kalra A; Gebreselassie SK; Thomas G; Hawkins ES; Svensson LG
EBioMedicine; 2020 Aug; 58():102907. PubMed ID: 32771682
[TBL] [Abstract][Full Text] [Related]
40. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.
Li J; Wang X; Chen J; Zhang H; Deng A
JAMA Cardiol; 2020 Jul; 5(7):825-830. PubMed ID: 32324209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]